eFFECTOR Therapeutics, Inc. (EFTR)
NASDAQ: EFTR · IEX Real-Time Price · USD
1.870
+0.090 (5.06%)
Apr 23, 2024, 12:12 PM EDT - Market open

eFFECTOR Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
03.551.43420
Revenue Growth (YoY)
-148.46%-96.60%--
Gross Profit
03.551.43420
Selling, General & Admin
10.9312.6413.374.354.72
Research & Development
22.9223.3119.9621.8323.89
Operating Expenses
33.8435.9633.3326.1828.61
Operating Income
-33.84-32.4-31.915.82-28.61
Interest Expense / Income
2.922.251.761.331.38
Other Expense / Income
-0.95-11.99-49.46-0.08-0.25
Pretax Income
-35.81-22.6715.814.56-29.74
Income Tax
0000.350
Net Income
-35.81-22.6715.814.21-29.74
Preferred Dividends
00014.05-15.53
Net Income Common
-35.81-22.6715.80.17-14.21
Net Income Growth
--9416.87%--
Shares Outstanding (Basic)
22100
Shares Outstanding (Diluted)
22100
Shares Change
32.77%14.37%1256.16%-78.56%-
EPS (Basic)
-16.37-13.7626.253.00-28.75
EPS (Diluted)
-16.37-13.7611.002.75-28.75
EPS Growth
--300.00%--
Free Cash Flow
-29.65-26.09-24.3213.68-27.51
Free Cash Flow Per Share
-13.56-15.84-40.25242.48-55.55
Gross Margin
-100.00%100.00%100.00%-
Operating Margin
--911.99%-2230.56%37.66%-
Profit Margin
--637.91%1104.76%0.40%-
Free Cash Flow Margin
--734.34%-1700.91%32.57%-
Effective Tax Rate
---2.41%-
EBITDA
-32.78-20.3617.5916.06-28.05
EBITDA Margin
--573.07%1229.79%38.23%-
Depreciation & Amortization
0.110.050.020.160.31
EBIT
-32.89-20.4117.5615.9-28.36
EBIT Margin
--574.56%1228.11%37.85%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).